Influx Health.

Why is Influx Healthtech Ltd falling/rising?

As of 09-Jun, Influx Healthtech Ltd's stock price is 232.90, showing a slight increase today but a significant decline of 16.25% over the past month. Despite recent challenges, it has a positive year-to-date return of 3.01%, indicating better long-term performance compared to the Sensex.

As of 09-Jun, Influx Healthtech Ltd's stock price is currently at 232.90, reflecting a slight increase of 0.25 (0.11%). Despite this minor rise, the stock has underperformed in the short term, with a 1-week decline of 2.10% compared to a 1.03% drop in the Sensex. Over the past month, the stock has experienced a significant decline of 16.25%, while the benchmark index fell by only 3.86%. <BR><BR>Year-to-date, however, Influx Healthtech Ltd shows a positive return of 3.01%, contrasting with the Sensex's decline of 11.05%. This indicates that while the stock has faced recent challenges, it has performed relatively well over a longer time frame. <BR><BR>Today's trading activity shows a rising investor participation, with a delivery volume increase of 11.73% against the 5-day average, suggesting growing interest among investors. The stock is also liquid enough for trading, based on its average traded value. <BR><BR>In terms of moving averages, the stock is currently above the 100-day and 200-day moving averages, but below the 5-day, 20-day, and 50-day moving averages, indicating mixed short-term momentum. <BR><BR>Overall, while the stock has seen a slight rise today, its recent performance trends and underperformance against the sector suggest that it is facing downward pressure in the short term.

Which are the latest news on Influx Health.?

Is Influx Health. overvalued or undervalued?

As of December 3, 2025, Influx Health is fairly valued with a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%, positioning it between peers Sun Pharma and Divi's Lab in terms of valuation.

As of 3 December 2025, Influx Health has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%. <BR><BR>In comparison to peers, Influx Health's PE ratio is higher than Sun Pharma's 37.51 and significantly lower than Divi's Lab's 68.92, which is categorized as very expensive. While the company has shown strong returns over the past week and month, outperforming the Sensex, its current valuation suggests that it is neither undervalued nor overvalued in the current market context.

How has been the historical performance of Influx Health.?

Influx Health showed positive financial performance from March 2024 to March 2025, with net sales increasing from 99.97 Cr to 104.85 Cr, operating profit rising from 16.96 Cr to 20.56 Cr, and profit after tax growing from 11.13 Cr to 13.37 Cr, despite a decrease in cash flow from operating activities. Total assets and liabilities both grew significantly, indicating balanced growth.

Answer:<BR>The historical performance of Influx Health shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Influx Health's net sales increased from 99.97 Cr in March 2024 to 104.85 Cr in March 2025, reflecting a growth in total operating income from 99.97 Cr to 104.85 Cr. The raw material cost decreased slightly from 65.27 Cr to 63.41 Cr, while employee costs rose from 7.04 Cr to 8.79 Cr. Total expenditure, excluding depreciation, increased from 83.01 Cr to 84.29 Cr. Operating profit (PBDIT) rose from 16.96 Cr to 20.56 Cr, leading to an operating profit margin improvement from 16.97% to 19.61%. Profit before tax also increased from 14.93 Cr to 17.88 Cr, with profit after tax rising from 11.13 Cr to 13.37 Cr, resulting in a PAT margin increase from 11.13% to 12.75%. The company's total assets grew significantly from 40.82 Cr to 70.12 Cr, while total liabilities increased from 40.82 Cr to 70.12 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities decreased from 8.00 Cr to 7.00 Cr, contributing to a net cash outflow of 1.00 Cr in March 2025, compared to no outflow in the previous year. Overall, Influx Health demonstrated a strong performance with improvements in profitability and asset growth.